Clinical review: Anti-TNFα therapies in uveitis: Perspective on 5 years of clinical experience

Ocular Immunology and Inflammation

Volumn 17, Issue 6, 2009, Pages 403-414

  Sharma, Srilakshmi M ^a   Nestel, Achim R ^a   Lee, Richard W J ^a   Dick, Andrew D ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Inflammatory cytokines; Intraocular inflammation; PSII; Recombinant antibodies; TNF ; Uveitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CENTOCOR; CERTOLIZUMAB PEGOL; CYCLOSPORIN; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; AUTOINFLAMMATORY DISEASE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; EYE INFLAMMATION; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MALIGNANT NEOPLASTIC DISEASE; REMISSION; REVIEW; SARCOIDOSIS; SCLERITIS; UVEITIS;

ANTIBODIES; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; EVIDENCE-BASED MEDICINE; HUMANS; REMISSION INDUCTION; RETREATMENT; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 72449188143     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273940903072443     Document Type: Review

References (131)

1. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Attract Study Group. Lancet. 1999;354(9194):1932-1939.
2. Murphy CC, Duncan L, Forrester JV, et al. Systemic CD4+ T cell phenotype and activation status in intermediate uveitis.Br J Ophthalmol. 2004 Mar;88(3):412-416.
3. Murphy CC, Ayliffe WH, Booth A, et al. Tumor necrosis factor [alpha] blockade with infliximab for refractory uveitis and scleritis.Ophthalmology. 2004;111(2):352-356.
4. Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease: an open-label trial. Arthritis Rheum. 2005;52(8):2478-2484.
5. Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthmol. 2005 Jul;123(7):903-912.
6. Lin, J, Ziring D, Desai S, et al. TNF-alpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol. 2008;126(1):13-30.
7. White ES, Lynch JP.Pharmacological therapy for Wegener's granulomatosis.Drugs. 2006;66(9):1209-1228.
8. Nussenblatt RB. The natural history of uveitis. Int Ophthalmol. 1990;14(5-6):303-308.
9. Tran VT, Auer C, Guex-Crosier Y, et al. Epidemiological characteristics of uveitis in Switzerland. Int Ophthalmol. 1994;18(5):293-298.
10. Baarsma GS. The epidemiology and genetics of endogenous uveitis: a review. Curr Eye Res.1992;11(suppl):1-9.
11. Miettinen, R.Incidence of uveitis in Northern Finland. Acta Ophthalmol (Copenh).1977;55(2):252-260
12. Mortensen KK, SA, Goldschmidt E.Uveitis, eine epidemiologische untersuchung. Ber Dtsch Ophthalmol Ges. 1981;78:97-101.
13. Gritz, DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study.Ophthalmology. 2004;111(3):491-500; discussion 500.
14. Rothova A, Suttorp-van Schulten MS, Treffers WF, et al. Causes and frequency of blindness in patients with intraocular inflammatory disease.Br J Ophthalmol. 1996;80(4):332-336.
15. Chiang YP, Bassi LJ, Javitt JC. Federal budgetary costs of blindness. Milbank Q. 1992;70(2):319-340.
16. Calder CJ, Nicholson LB, Dick AD. A selective role for the TNF P55 receptor in autocrine signaling following IFN-gamma stimulation in experimental autoimmune uveoretinitis. J Immunol. 2005;175(10):6286-6293.
17. Ruuls SR, Hoek RM, Ngo VN, et al. Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity. 2001;15(4):533-543.
18. Turan B, Pfister K, Diener PA, et al. Soluble tumour necrosis factor receptors STNFR1 and STNFR2 are produced at sites of inflammation and are markers of arthritis activity in Behcet's disease. Scand J Rheumatol. 2008;37(2):135-141.
19. Sugita S, Takase H, Taguchi C, et al. The role of soluble TNF receptors for TNF-alpha in uveitis. Invest Ophthalmol Vis Sci. 2007;48(7):3246-3252.
20. Dick AD, Forrester JV, Liversidge J, et al. The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Prog Retin Eye Res.2004;23(6):617-637.
21. Dick AD, Duncan L, Hale G, et al. Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis.J Autoimmun.1998;11(3):255-264.
22. Robertson M, Liversidge J, Forrester JV, et al. Neutralizing tumor necrosis factor-alpha activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci.2003;44(7):3034-3041.
23. Dick AD, McMenamin PG, Korner H, et al. Inhibition of tumor necrosis factor activity minimizes target organdamage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina. Eur J Immunol. 1996;26(5):1018-1025.
24. Sartani G, Silver PB, Rizzo LV, et al. Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming. Invest Ophthalmol Vis Sci. 1996;37(11):2211-2218.
25. Nakamura S, Yamakawa T, Sugita M, et al. The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice.Invest Ophthalmol Vis Sci.1994;35(11):3884-3889.
26. Hankey DJ, Lightman SL, Baker D. Interphotoreceptor retinoid binding protein peptide-induced uveitis in B10. RIII mice: characterization of disease parameters and immunomodulation. Exp Eye Res.2001;72(3):341-350.
27. Greiner K, Murphy CC, Willermain F, et al. Anti-TNFalpha therapy modulates the phenotype of peripheral blood CD4+ T cells in patients with posterior segment intraocular inflammation. Invest Ophthalmol Vis Sci. 2004;45(1):170-176.
28. Hamzaoui K, Hamzaoui A, Houman H. CD4+CD25+ regulatory T cells in patients with Behcet's disease. Clin Exp Rheumatol. 2006;24(5)(suppl42):S71-S78.
29. Hoyer KK, Dooms H, Barron L, et al. Interleukin-2 in the development and control of inflammatory disease.Immunol Rev. 2008;226:19-28.
30. Kavanaugh A, St Clair EW, McCune WJ, et al. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol. 2000;27(4):841-850.
31. Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum. 2005;34(5) (suppl1):12-18.
32. Braun J, Davis J, Dougados M, et al. First update of the international ASAS consensus statement for the use of anti- TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2006;65(3):316-320.
33. Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis.Arthritis Rheum. 2005;53(1):18-23.
34. Inman RD, Davis, Jr JC, Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58(11):3402-3412.
35. Jabs DA. Improving the reporting of clinical case series. Am J Ophthalmol. 2005;139(5):900-905.
36. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509-516.
37. Murphy CC, Greiner K, Plskova J, et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol. 2005;123(5):634-641.
38. Galor A, Jabs DA, Leder HA, et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology, 2008;115(10):1826-1832.
39. Hogan AC, McAvoy CE, Dick AD, et al. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology. 2007;114(5):1000-1006.
40. Teoh SC, Hogan AC, Dick AD, et al. Mycophenolate mofetil for the treatment of uveitis. Am J Ophthalmol. 2008;146(5):752-760, 760 e1-3.
41. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med. 1990;322(5):281-285. (Pubitemid 20046329)
42. Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behcet's syndrome: effects on long-term prognosis. Arthritis Rheum. 1997;40(4):769-774.
43. Sakane T, Takeno M, Suzuki N, et al. Behcet's disease. N Engl J Med. 1999;341(17):1284-1291.
44. Samson CM, Waheed N, Baltatzis S, et al. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology. 2001;108(6):1134-1139.
45. Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol. 2007;18(6):481-486.
46. Murphy CC, Greiner K, Plskova J, et al. Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis. Arch Ophthalmol. 2004;122(6):845-851.
47. Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. Ann Intern Med. 2004;140(5):404-406.
48. Niccoli L, Nannini C, Benucci M, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study. Rheumatology (Oxford). 2007;46(7):1161-1164.
49. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol. 2004;31(7):1362-1368.
50. Misumi M, Hagiwara E, Takeno M, et al. Cytokine production profile in patients with Behcet's disease treated with infliximab. Cytokine. 2003;24(5):210-218.
51. Rudwaleit M, Rodevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis. 2009 May; 68(5):696-701.
52. Gonvers JJ, Juillerat P, Mottet C, et al. Maintenance of medically induced remission of Crohn's disease. Digestion. 2007;76(2):116-129. (Pubitemid 351194906)
53. Breban M, Ravaud P, Claudepierre P, et al. Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum. 2008;58(1):88-97.
54. Accorinti M, Pirraglia MP, Paroli MP, et al. Infliximab treatment for ocular and extraocular manifestations of Behcet's disease. Jpn J Ophthalmol. 2007;51(3):191-196.
55. Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behcet disease. Am J Ophthalmol. 2008;146(6):845-850 e1.
56. NICE Guidelines. CG33 Tuberculosis: Full Guideline. 2006. http://www.cdc.gov/tb/topic/testing/default.htm. Last updated 1 June 2009. accessed 12 April 2009.
57. Centre for Disease Communication. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of Tuberculosis Elimination( DTBE). TB Guidelines- Diagnosis. 2008. www.cdc.gov/tb/pubs/mmwr/Maj- guide/Diagnosis.htm.
58. Baars JE, Siegel CA, Kuipers EJ, et al. Patient's perspectives important for early anti-tumor necrosis factor treatment in inflammatory bowel disease. Digestion. 2009;79(1):30-35.
59. Nakamura S, Ohno S. Anti-Tumor necrosis factor alpha antibody in the treatment of Behcet's disease. Int Ophthalmol Clin. 2005;45(2):179-189.
60. Kahn P, Weiss M, Imundo LF, et al. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology. 2006;113(5):860-864. e2.
61. Conaghan PG, Quinn MA, O'Connor P, et al. Can very high-dose anti-tumor necrosis factor blockade at onset of rheumatoid arthritis produce long-term remission? Arthritis Rheum. 2002;46(7):1971-1972; author reply 1973.
62. Rudwaleit M, Claudepierre P, Wordsworth P, et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol. 2009;36(4):801-808.
63. Schreiber S, Sandborn WJ. Classic-I study the efficacy of adalimumab. Gastroenterology. 2006;130(6):1929-1930.
64. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66(7):921-926.
65. TA130 Rheumatoid Arthritis-adalimum ab, etanercept and mFliximab: guidance. National Institute for Health and Clinical Excellence, 22 October 2007. http://www.nice.org. UK/guidance/TA130. Accessed 10 April 2009.
66. Mushtaq B, Saeed T, Situnayake RD, et al. Adalimumab for sight-threatening uveitis in Behcet's disease. Eye. 2007;21(6):824-825.
67. Sharma SM, Ramanan AV, Riley P, et al. Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease. Ann Rheum Dis. 2007 Jun;66(6): 840-841.
68. Hansen KE, Hildebrand JP, Genovese MC, et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol. 2004;31(6):1098-1102.
69. Favalli EG, Arreghini M, Arnoldi C, et al. Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis. Arthritis Rheum. 2004;51(2):301-302.
70. Kocharla L, Mongey AB. Is the development of drugrelated lupus a contraindication for switching from one TNF alpha inhibitor to another? Lupus. 2009;18(2):169-171.
71. Hyrich KL, Watson KD, Isenberg DA, et al. The British Society for Rheumatology Biologics Register: 6 years on. Rheumatology (Oxford). 2008;47(10):1441-1443.
72. Carmona L, Gomez-Reino JJ. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis: data from the Spanish Registry Biobadaser. Arthritis Res Ther. 2006;8(3):R72.
73. Gomez-Reino JJ, Carmona L. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther. 2006;8(1):R29.
74. Bombardieri S, Ruiz AA, Fardellone P, et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford). 2007;46(7):1191-1199.
75. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348(7):601-608. (Pubitemid 36204954)
76. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41(9):1552-1563.
77. De Bandt M, Sibilia J, Le Loet X, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 2005;7(3):R545-R551.
78. Gran JT, Skomsvoll JF. The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol. 1997;36(7):766-771.
79. Braun J, Baraliakos X, Listing J, et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005;52(8):2447-2451.
80. Guignard S, Gossec L, Salliot C, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis. 2006;65(12):1631-1634.
81. Ardoin SP, Kredich D, Rabinovich E, et al. Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am J Ophthalmol. 2007;144(6):844-849.e1.
82. Foeldvari I, Nielsen S, Kummerle-Deschner J, et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to secondline agents: results of a multinational survey. J Rheumatol. 2007;34(5):1146-1150.
83. Gallagher M, Quinones K, Cervantes-Castaneda RA, et al. Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol. 2007 Oct; 91(10):1341-1344.
84. Saurenmann RK, Levin AV, Rose JB, Parker S, Rabinovitch T, Tyrrell PN, Feldman BM, Laxer RM, Schneider R, Silverman ED. Tumour Necrosis Factor {Alpha} Inhibitors in the Treatment of Childhood Uveitis. Rheumatology (Oxford). 2006 Aug; 45(8):982-989.
85. Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr. 2006;149(4):572-575.
86. Biester, S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007;91(3):319-324.
87. Ziegenhagen MW, Muller-Quernheim J. The cytokine network in sarcoidosis and its clinical relevance. J Intern Med. 2003;253(1):18-30.
88. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357(21):2153-2165.
89. Kaiser PK, Lowder CY, Sullivan P, et al. Chest computerized tomography in the evaluation of uveitis in elderly women. Am J Ophthalmol. 2002;133(4):499-505.
90. Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174(7):795-802.
91. Ramos-Casals M, Brito-Zeron P, Munoz S, et al. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore). 2008;87(6):345-364.
92. Curnow SJ, Pryce K, Modi N, et al. Serum cytokine profiles in Behcet's disease: is there a role for Il-15 in pathogenesis? Immunol Lett. 2008;121(1):7-12.
93. Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study. J Rheumatol. 2005;32(1):98-105.
94. Mamo JG. The rate of visual loss in Behcet's disease. Arch Ophthalmol. 1970;84(4):451-452.
95. Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behcet disease. Ann Rheum Dis. 2008;67(12):1656-1662.
96. Hatemi G, Silman A, Bang D, et al. Management of Behcet's disease: a systematic literature review for the EULAR evidence based recommendations for the management of Behcet's disease. Ann Rheum Dis. 2008 Apr 17.
97. Ozyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet's syndrome: a single masked trial. Br J Ophthalmol. 1992;76(4):241-243.
98. BenEzra D, Cohen E, Chajek T, et al. Evaluation of conventional therapy versus cyclosporine A in Behcet's syndrome. Transplant Proc. 1988;20(3)(suppl 4): 136-143.
99. Masuda K, Nakajima A, Urayama A, et al. Doublemasked trial of cyclosporin versus colchicine and longterm open study of cyclosporin in Behcet's disease. Lancet. 1989;1(8647):1093-1096.
100. Isnard Bagnis C, Tezenas du Montcel S, Beaufils H, et al. Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study. J Am Soc Nephrol. 2002;13(12):2962-2968.
101. Burmester GR, Mease PJ, Dijkmans BA, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis. 2009 Jan 15.
102. Gerloni V, Pontikaki I, Gattinara M, et al. Focus on adverse events of TNF{alpha} blockade in JIA in an open monocentric long-term prospective study of 163 patients. 2007. p. ard.2007.069484.
103. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum. 2008 Dec 29 [Epub ahead of print].
104. Salgame P. Host innate and TH1 responses and the bacterial factors that control mycobacterium tuberculosis infection. Curr Opin Immunol. 2005;17(4):374-380.
105. Taylor RE, Cant AJ, Clark JE. Potential effect of NICE tuberculosis guidelines on paediatric tuberculosis screening. Arch Dis Child. 2008;93(3):200-203.
106. Gomez-Reino J, Carmona L. Recommendations to lower the risk of tuberculosis in patients treated with tumour necrosis factor alpha antagonists. Acta Reumatol Port. 2006;31(3):201-203.
107. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 2005;52(6):1766-1772.
108. Wallis RS. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis. 2008;8(10):601-611.
109. Blackmore TK, Manning L, Taylor WJ, et al. Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. Clin Infect Dis. 2008;47(10):e83-85.
110. Feldmann M, Maini RN. Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies. Joint Bone Spine. 2002;69(1):12-18.
111. Toussirot E, Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview. Expert Opin Pharmacother. 2004;5(3):581-594.
112. Lens SM, Tesselaar K, den Drijver BF. et al. A dual role for both CD40-ligand and TNF-alpha in controlling human B cell death. J Immunol. 1996;156(2):507-514.
113. Wallgren A, Festin R, Gidlof C, et al. Efficient killing of chronic B-lymphocytic leukemia cells by superantigendirected T cells. Blood. 1993;82(4):1230-1238.
114. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002;46(12):3151-3158.
115. Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006 Jul; 65(7):889-894.
116. Spillane AP, Xia Y, Sniezek PJ. Drug-induced lupus erythematosus in a patient treated with adalumimab. J Am Acad Dermatol. 2007; 56(5)(suppl):S114- S116.
117. Peek R, Scott-Jupp R, Strike H, et al. Psoriasis after treatment of juvenile idiopathic arthritis with etanercept. Ann Rheum Dis. 2006;65(9):1259.
118. Lim LL, Fraunfelder FW, Rosenbaum JT. Arthritis Rheum. 2007 Oct; 56(10): 3248-3252.
119. Coates LC, McGonagle DG, Bennett AN, et al. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis. Ann Rheum Dis. 2008;67(5):729-730.
120. Furrer E, Berdugo M, Stella C, et al. Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye. Invest Ophthalmol Vis Sci. 2009;50(2):771-778.
121. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26-37.
122. Smolen JS, Van Der Heijde DM, St Clair EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum. 2006;54(3):702-710.
123. Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52(1):27-35.
124. Caramaschi P, Pieropan S, Volpe A, et al. [Sustained response to infliximab treatment in two cases of early rheumatoid arthritis that has been maintained after drug withdrawal]. Reumatismo. 2008;60(3):221-223.
125. Bodaghi B, Gendron G, Wechsler B, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol. 2007 Mar; 91(3):335-339.
126. Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behcet disease: a randomized placebocontrolled and double-blind study. Arch Dermatol. 2002 Apr; 138(4):467-471.
127. Wechsler B, Bodaghi B, Huong DL, et al. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behcet's disease. Ocul Immunol Inflamm. 2000;8(4):293-301.
128. Krause L, Turnbull JR, Torun N, et al. Interferon alfa-2a in the treatment of ocular Adamantiades-Behcet's disease. Adv Exp Med Biol. 2003;528:511-519.
129. Krause L, Altenburg A, Pleyer U, et al. Long-term visual prognosis of patients with ocular Adamantiades-Behcet's disease treated with interferon-alpha-2a. J Rheumatol. 2008;35(5):896-903.
130. Lindstedt EW, Baarsma GS, Kuijpers RW, et al. Anti- TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol. 2005;89(5):533-536.
131. Bodaghi B, Bui Quoc E, Wechsler B, et al. Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors. Ann Rheum Dis. 2005;64(6):962-964.